Hologic Inc

Hologic — Q4 2024 Earnings Presentation

46 slides from Hologic's earnings presentation, Nov 4, 2024

  1. Slide 1: Hologic: Bigger. Faster. Stronger.

    HOLOGIC Bigger. Faster. Stronger. November 2024 1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or other

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures The Company has presented the following non-GAAP financial measures in this presentation: constant currency revenues; organic revenues; organic revenues excluding COVID-19, non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective t

  4. Slide 4: Presentation Outline

    Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 4

  5. Slide 5: Investment Thesis: Hologic

    Investment Thesis: Hologic • Overview: ○ Purpose Driven. Results Driven. ○ Engaged and dependable • Bigger: ○ A larger company, with more durable revenue • Faster: ○ An improved projected growth algorithm ○ Diversified contributions • Stronger: ○ Exceptionally strong balance sheet ○ Robust FCF gener

  6. Slide 6: Purpose Driven.

    Purpose Driven. The Hologic Virtuous Circle Championing Women's Health • The Hologic Global Women’s Health Index • Project Health Equity • Global Access Initiative • WTA Partnership Driving Core Growth & Creating New Markets 6

  7. Slide 7: Purpose Driven. Results Driven.

    Purpose Driven. Results Driven. The Hologic Virtuous Circle Financial Profile • Diverse and Durable Revenue Growth Drivers • Strong Margin Profile • Entire P&L Utilized for EPS Growth • Fortress Balance Sheet 7 *Organic revenue excludes revenue from divested businesses and revenue from acquisitions

  8. Slide 8: Board of Directors

    Board of Directors Steve MacMillan Sally W. Crawford Charles J. Dockendorff Scott Garrett Stacey D. Stewart Nanaz Mohtashami Christiana Stamoulis Amy M. Wendell Ludwig N. Hantson 8

  9. Slide 9: Our Engaged and Exceptional Teams…

    Our Engaged and Exceptional Teams… A Highly Engaged A Great Place to Work Workforce • 95% - “When I look at what we Gallup Q12 Survey Results accomplish, I feel a sense of pride” 100% 96% 96% 96% 97% 83% • 95% - “I’m proud to tell others I work 80% 73% here” 63% 64% 60% • 93% - “I feel good about th

  10. Slide 10: …Grow and Drive Dependable Financial Results.

    …Grow and Drive Dependable Financial Results. • 5.3% • Delivered MSD Organic ex. COVID growth in FY24 • Returned to total company top-line growth in 2H’24 10 Note: FY24 Organic revenue excludes the acquired Endomagnetics business and the divested Blood Screening and SSI businesses. Organic revenue e

  11. Slide 11: …Grow and Drive Dependable Financial Results.

    …Grow and Drive Dependable Financial Results. • 5.3% • Delivered MSD Organic ex. COVID growth in FY24 • Returned to total company top-line growth in 2H’24 • $2.4 Billion • Cash and Investments on our balance sheet at the end of Q4’24 11 Note: FY24 Organic revenue excludes the acquired Endomagnetics

  12. Slide 12: …Grow and Drive Dependable Financial Results.

    …Grow and Drive Dependable Financial Results. • 5.3% • Delivered MSD Organic ex. COVID growth in FY24 • Returned to total company top-line growth in 2H’24 • $2.4 Billion • Cash and Investments on our balance sheet at the end of Q4’24 • 14 Quarters • Consistently delivered on robust Revenue and EPS g

  13. Slide 13: …Grow and Drive Dependable Financial Results.

    …Grow and Drive Dependable Financial Results. • 5.3% • Delivered MSD Organic ex. COVID growth in FY24 • Returned to total company top-line growth in 2H’24 • $2.4 Billion • Cash and Investments on our balance sheet at the end of Q4’24 • 14 Quarters • Consistently delivered on robust Revenue and EPS g

  14. Slide 14: Poised for Future Success.

    Poised for Future Success. • Bigger, Faster, Stronger • Forged during COVID and macro volatility • Fortified balance sheet to continue strong capital deployment • Well positioned to maximize opportunity and realize potential 14

  15. Slide 15: You Can Count on Us to Deliver.

    You Can Count on Us to Deliver. • A solid Q4’24, with Organic ex. COVID growth in MSDs. Q4’24 Revenue Q4’23 Revenue Change (CC) Diagnostics $443.3 $416.4 6.2% Organic Diagnostics ex. $395.7 $361.4 9.2% COVID Organic Molecular $279.2 $246.2 13.2% Diagnostics ex. COVID Breast Health $375.5 $352.8 6.2%

  16. Slide 16: Presentation Outline

    Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 16

  17. Slide 17: Hologic is a Bigger and more Durable Company Post Pandemic.

    Hologic is a Bigger and more Durable Company Post Pandemic. • Maximized opportunities through macro volatility; significant potential ahead Total Hologic Global Revenue Organic ex. COVID-19* $4,000 $3,807 $3,500 $3,000 $2,876 $2,500 $2,000 $1,500 $1,000 $500 $0 2019 2024 Note: Dollars in millions. *

  18. Slide 18: In Diagnostics we are More than 50% Larger

    In Diagnostics we are More than 50% Larger and in Molecular Diagnostics we are Nearly 100% Larger… Global Diagnostics Revenue Organic ex. COVID-19* Global Molecular Diagnostics Revenue Organic ex. COVID-19* $1,800 $1,200 $1,569 $1,090 $1,600 $1,000 $1,400 $1,200 $800 $1,029 $1,000 $600 $557 $800 $60

  19. Slide 19: …Leveraging a Significantly Expanded Panther Footprint…

    …Leveraging a Significantly Expanded Panther Footprint… Global Panther Installed Base 3,500 ~3,300 3,000 2,500 2,000 ~1,700 1,500 1,000 500 0 2019 2024 19

  20. Slide 20: …And Continuing to Innovate.

    …And Continuing to Innovate. • Genius Digital Diagnostics System Now Available Worldwide o Highlighting our focus on workflow automation and AI 20

  21. Slide 21: In Breast Health we are More Than 15% Larger

    In Breast Health we are More Than 15% Larger with More Recurring Revenue. • A larger and more resilient franchise Global Breast Health Revenue $1,600 $1,523 $1,400 $1,314 14% $1,200 16% 22% $1,000 19% $800 24% 29% $600 $400 36% 40% $200 $0 2019 2024 Service Gantries Interventional* Accessories and E

  22. Slide 22: And in Surgical we are Nearly 50% Larger…

    And in Surgical we are Nearly 50% Larger… Global Surgical Revenue $700 $641 $600 $500 $437 $400 $300 $200 $100 $0 2019 2024 Note: Dollars in millions. 22 ,

  23. Slide 23: …with Increasingly Diversified Revenue.

    …with Increasingly Diversified Revenue. • New growth drivers: o Less than 10% of FY19 revenue vs. more than 20% of FY24 revenue Global Surgical Revenue $641 $437 2019 2024 NovaSure Core MyoSure Fluid Management Laparoscopy Other 23 Note: Dollars in millions. New growth drivers include revenue from F

  24. Slide 24: Presentation Outline

    Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 24

  25. Slide 25: Hologic is a Faster Growing Company Today

    Hologic is a Faster Growing Company Today • Grounded in our Strong Core, Market-Leading Products… • ThinPrep, Aptima STIs, 3D Mammography, NovaSure, MyoSure Intl Opportunity New Growth Drivers Strong Foundation Strong Foundation 25 Note: Organic revenue excludes revenue from divested businesses and

  26. Slide 26: Hologic is a Faster Growing Company Today

    Hologic is a Faster Growing Company Today • Grounded in our Strong Core, Market-Leading Products… • ThinPrep, Aptima STIs, 3D Mammography, NovaSure, MyoSure Intl • …With New Growth Drivers, in New Markets… Opportunity • Organic + Inorganic + Market Creation • BV CV/TV, BCI, Brevera, Fluent, Acessa,

  27. Slide 27: Hologic is a Faster Growing Company Today

    Hologic is a Faster Growing Company Today • Grounded in our Strong Core, Market-Leading Products… • ThinPrep, Aptima STIs, 3D Mammography, NovaSure, MyoSure Intl Intl • …With New Growth Drivers, in New Markets… Opportunity Opportunity • Organic + Inorganic + Market Creation • BV CV/TV, BCI, Brevera,

  28. Slide 28: Hologic is a Faster Growing Company Today

    Hologic is a Faster Growing Company Today • Grounded in our Strong Core, Market-Leading Products… • ThinPrep, Aptima STIs, 3D Mammography, NovaSure, MyoSure Intl Intl • …With New Growth Drivers, in New Markets… Opportunity Opportunity • Organic + Inorganic + Market Creation • BV CV/TV, BCI, Brevera,

  29. Slide 29: Presentation Outline

    Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 29

  30. Slide 30: Strong Balance Sheet with Proven Commitment to Returning Capital

    Strong Balance Sheet with Proven Commitment to Returning Capital Net Debt and Leverage Ratio* Diluted Shares Outstanding $4.0 280.0 $3.5 271.3 270.0 264.6 4.0x $3.1 259.7 $3.0 $2.8 $2.8 260.0 253.8 3.3x $2.6 $2.5 248.8 2.8x $2.3 250.0 2.7x 2.6x 2.3x 237.6 $2.0 1.5x $1.9 240.0 0.6x 230.0 0.6x 220.0 $

  31. Slide 31: More than $7.0 Billion in FCF over the Past 5 Years

    More than $7.0 Billion in FCF over the Past 5 Years Over $4.6 Billion Deployed Since FY’20 M&A Accelerates Growth • Redeployed FCF* to drive growth across • 7 deals across each division the entire P&L ○ Diagnostics • Over $1.7 billion on M&A** – Biotheranostics, Diagenode, Mobidiag ○ Breast Health •

  32. Slide 32: Presentation Outline

    Presentation Outline Overview Bigger Faster Stronger Conclusion and Financials 32

  33. Slide 33: Investment Thesis: Hologic

    Investment Thesis: Hologic • Overview: ○ Purpose Driven. Results Driven. ○ Engaged and dependable • Bigger: ○ A larger company, with more durable revenue • Faster: ○ An improved projected growth algorithm ○ Diversified contributions • Stronger: ○ Exceptionally strong balance sheet ○ Robust FCF gener

  34. Slide 34: Financial Overview Q4’24

    Financial Overview Q4’24 Non-GAAP $M, except EPS Q4’24 ∆ vs. Q4’23 Revenue $987.9 4.5% and 4.2% CC Organic $973.0 4.4% and 4.2% CC Organic ex COVID $933.0 5.3% and 5.0% CC Gross Margin 61.5% 110 bps Operating Expenses $311.0 2.4% Operating Margin 30.0% 170 bps Net Margin 24.0% 80 bps Diluted EPS $1.

  35. Slide 35: 2025 & Q1’25 Financial Guidance

    2025 & Q1’25 Financial Guidance 2025 Full Year* Q1’25* Guidance Guidance Revenue $4,150 – $4,200 $1,025 – $1,035 GAAP Diluted EPS $3.53 – $3.63 $0.81 – $0.84 Non-GAAP Diluted EPS $4.25 – $4.35 $1.00 – $1.03 • Expect fiscal 2025 organic revenue ex. COVID growth at the midpoint to be 4.1%. * Dollars i

  36. Slide 36: Appendix

    Appendix HOLOGIC' |

  37. Slide 37: Hologic Overview

    Hologic Overview • Revenue of $4,030 million in fiscal 2024 By Division By Type By Geography Surgical Service 16% and Other INTL 19% 25% Diagnostics 44% Capital Consumables 19% 62% Breast and Skeletal US 40% 75% Note: Percentages in pie charts are for FY24. 37

  38. Slide 38: A Growing Base Business…

    A Growing Base Business… Total Revenue* 46.5% $6,000 $5,632 -12.3% $4,863 $5,000 -16.3% -0.2% 12.1% $2,160 $4,030 5.7% $3,776 $1,431 $4,030 $79 $4,000 8.3% 4.3% $248 $3,218 $3,367 5.4% $3,059 $929 $3,000 0.4% 9.9% $2,000 $1,000 $2,511 $2,705 $2,833 $2,851 $2,879 $3,052 $2,782 $3,473 $3,433 $3,782 $3

  39. Slide 39: …with Robust Profitability.

    …with Robust Profitability. Non-GAAP EPS* $9.00 111.3% $8.00 $7.00 -28.4% $6.00 $5.00 $4.00 63.8% -34.2% 3.0% $3.00 9.9% 9.0% 17.4% 3.6% $2.00 14.4% -2.7% $1.00 $6.02 $3.96 $4.08 $1.46 $1.67 $1.96 $2.03 $2.23 $2.43 $3.98 $8.41 $0.00 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 *Non-GAAP EP

  40. Slide 40: COVID Assay and COVID Related Revenue

    COVID Assay and COVID Related Revenue COVID Assay and COVID Related Revenue* $823 $800 $760 $700 $664 $661 $600 $596 $514 $500 $400 $365 $352 $300 $215 $200 $187 $163 $100 $98 $27 $55 $45 $52 $53 $38 $40 $23 $0 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24

  41. Slide 41: Capitalization as of Q4’24

    Capitalization as of Q4’24 Tranche Amount Leverage Coupon Rating Call Date Maturity Cash & Equivalents 2,160 Revolving Facility $2B - SOFR + 110 Baa3 / BBB- 09/25/26 Term Loan 1,198 SOFR + 110 Baa3 / BBB- 09/25/26 Total Secured Debt 1,198 0.9x Senior Unsecured Notes - 2028 400 4.625% Ba2 / BB+ 02/01

  42. Slide 42: Reconciliation of GAAP to Non-GAAP (unaudited)

    Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended September 28, 2024 September 30, 2023 GROSS PROFIT GAAP gross profit $557.7 $500.3 Adjustments: Amortization of acquired intangible assets 45.5 46.4 Product line discontinuance - 24.7 Fair val

  43. Slide 43: Reconciliation of GAAP to Non-GAAP (unaudited)

    Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended September 28, 2024 September 30, 2023 OPERATING MARGIN GAAP income from operations $230.1 $132.5 Adjustments to gross profit as detailed above 49.8 71.1 Adjustments to operating expenses as de

  44. Slide 44: Definitions

    Definitions • Organic Revenue: Total constant currency revenue excluding the divested Blood Screening business and revenue from acquired businesses owned by Hologic for less than one year. In fiscal 2024, organic revenue excludes the divested SSI ultrasound imaging business and the acquired Endomagn

  45. Slide 45: Our Core Strengths Create the Foundation for Diversified Durable Growth

    *\ Our Core Strengths Create the Foundation for Diversified Durable Growth and Dependable Performance. HOLOGIC’ ‘As a global medical technology innovator leading the way in women's health, Hologic delivers life-changing and lifesaving detection, diagnostic and treatment solutions. Our products are r

  46. Slide 46: For More Information: Ryan Simon, VP Investor Relations

    For More Information: Ryan Simon VP, Investor Relations ryan.simon@hologic.com 46

Hologic — Q4 2024 Earnings Presentation on 6ix